Use of Copeptin Measurement After Arginine Infusion for the Differential Diagnosis of Diabetes Insipidus - the CARGOx Study (CARGOx)
Primary Purpose
Diabetes Insipidus, Polydipsia, Primary
Status
Completed
Phase
Not Applicable
Locations
International
Study Type
Interventional
Intervention
Arginine infusion
Hypertonic saline infusion
Sponsored by
About this trial
This is an interventional diagnostic trial for Diabetes Insipidus focused on measuring Copeptin
Eligibility Criteria
Inclusion Criteria:
- Age ≥ 18 years
- Hypotonic polyuria / polydipsia syndrome defined as: polyuria >50ml/kg body weight/24h and polydipsia >3l /24h or known diabetes insipidus under treatment with DDAVP
- Urine-Osmolality <800mOsm/L
Exclusion Criteria:
- Polyuria / polydipsia secondary to diabetes mellitus, hypercalcemia or hypokalemia
- Nephrogenic diabetes insipidus (defined as baseline copeptin level >21.4pmol/L)
- Evidence of any acute illness
- Epilepsy requiring treatment
- Uncontrolled arterial hypertension (blood pressure >160/100mmHg at baseline)
- Cardiac failure (NYHA III-IV)
- Liver cirrhosis (Child B-C)
- Uncorrected adrenal or thyroidal deficiency
- Patients refusing or unable to give written informed consent
- Pregnancy or breast feeding
- End of life care
Sites / Locations
- Hospital das clinicas Minas Gerais
- University Hospital Würzburg
- Granda Ospedale Maggiore Policlinico Milan
- Erasmus MC
- University Hospital Basel, Department of Endocrinology
- University Hospital Zurich
- Cambridge University Hospital
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Active Comparator
Arm Label
Arginine Infusion
Hypertonic saline infusion
Arm Description
Arginine Stimulation Test
Hypertonic Saline Infusion Test
Outcomes
Primary Outcome Measures
The primary outcome is the overall diagnostic accuracy - defined as the proportion of correct diagnoses - of each diagnostic procedure in differentiating patients with central diabetes insipidus from patients with primary polydipsia.
For Arginine stimulation the copeptin cut-off to differentiate between diabetes insipidus and primary polydipsia will be 3.8 pmol/l after 60 minutes, for hypertonic saline stimulation it will be the copeptin cut-off 4.9 pmol/l taken at the end of the test
Secondary Outcome Measures
Sensitivity of both diagnostic procedures for each diagnosis (Primary polydipsia, partial and complete central Diabetes insipidus) according to recommended diagnostic test criteria and previously generated cutoff values
Copeptin cut-offs used:
Arginine stimulation:
Copeptin level at 60 minutes < 2.4 pmol/l = complete central diabetes insipidus
Copeptin level at 60 minutes 2.4 - 3.8 pmol/l = partial central diabetes insipidus
Copeptin level at 60 minutes > 3.8 pmol/l = primary polydipsia
Hypertonic saline stimulation:
Copeptin level < 2.7 pmol/l = complete central diabetes insipidus
Copeptin level 2.7 - 4.9 pmol/l = partial central diabetes insipidus
Copeptin level > 4.9 pmol/l = primary polydipsia
Specificity of both diagnostic procedures for each diagnosis (Primary polydipsia, partial and complete central Diabetes insipidus) according to recommended diagnostic test criteria and previously generated cutoff values
Copeptin cut-offs used:
Arginine stimulation:
Copeptin level at 60 minutes < 2.4 pmol/l = complete central diabetes insipidus
Copeptin level at 60 minutes 2.4 - 3.8 pmol/l = partial central diabetes insipidus
Copeptin level at 60 minutes > 3.8 pmol/l = primary polydipsia
Hypertonic saline stimulation:
Copeptin level < 2.7 pmol/l = complete central diabetes insipidus
Copeptin level 2.7 - 4.9 pmol/l = partial central diabetes insipidus
Copeptin level > 4.9 pmol/l = primary polydipsia
Positive predictive value of both diagnostic procedures for each diagnosis (Primary polydipsia, partial and complete central Diabetes insipidus) according to recommended diagnostic test criteria and previously generated cutoff values
Copeptin cut-offs used:
Arginine stimulation:
Copeptin level at 60 minutes < 2.4 pmol/l = complete central diabetes insipidus
Copeptin level at 60 minutes 2.4 - 3.8 pmol/l = partial central diabetes insipidus
Copeptin level at 60 minutes > 3.8 pmol/l = primary polydipsia
Hypertonic saline stimulation:
Copeptin level < 2.7 pmol/l = complete central diabetes insipidus
Copeptin level 2.7 - 4.9 pmol/l = partial central diabetes insipidus
Copeptin level > 4.9 pmol/l = primary polydipsia
Negative predictive value of both diagnostic procedures for each diagnosis (Primary polydipsia, partial and complete central Diabetes insipidus) according to recommended diagnostic test criteria and previously generated cutoff values
Copeptin cut-offs used:
Arginine stimulation:
Copeptin level at 60 minutes < 2.4 pmol/l = complete central diabetes insipidus
Copeptin level at 60 minutes 2.4 - 3.8 pmol/l = partial central diabetes insipidus
Copeptin level at 60 minutes > 3.8 pmol/l = primary polydipsia
Hypertonic saline stimulation:
Copeptin level < 2.7 pmol/l = complete central diabetes insipidus
Copeptin level 2.7 - 4.9 pmol/l = partial central diabetes insipidus
Copeptin level > 4.9 pmol/l = primary polydipsia
Best fit diagnostic copeptin cut-off values for differentiation between each diagnosis (Primary polydipsia, partial and complete central Diabetes insipidus) upon arginine stimulation and hypertonic saline infusion stimulation
Accuracy of the copeptin cut-off of 3.7 pmol/l after 60 minutes and 4.1 after 90 minutes for Arginine Stimulation test
Sensitivity of the copeptin cut-off of 3.7 pmol/l after 60 minutes and 4.1 after 90 minutes for Arginine Stimulation test
Specificity of the copeptin cut-off of 3.7 pmol/l after 60 minutes and 4.1 after 90 minutes for Arginine Stimulation test
Accuracy of the copeptin cut-off of 6.5 pmol/l for Hypertonic Saline Infusion test
Sensitivity of the copeptin cut-off of 6.5 pmol/l for Hypertonic Saline Infusion test
Specificity of the copeptin cut-off of 6.5 pmol/l for Hypertonic Saline Infusion test
Frequency and severity of thirst assessed by visual analogue scale during both tests
assessed by visual analogue scale from 0 to 10, with 0 indicating no symptoms and 10 indicating severe symptoms.
Frequency and severity of headache assessed by visual analogue scale during both tests
assessed by visual analogue scale from 0 to 10, with 0 indicating no symptoms and 10 indicating severe symptoms.
Frequency and severity of nausea assessed by visual analogue scale during both tests
assessed by visual analogue scale from 0 to 10, with 0 indicating no symptoms and 10 indicating severe symptoms.
Frequency and severity of vertigo assessed by visual analogue scale during both tests
assessed by visual analogue scale from 0 to 10, with 0 indicating no symptoms and 10 indicating severe symptoms.
Frequency and severity of general malaise assessed by visual analogue scale during both tests
assessed by visual analogue scale from 0 to 10, with 0 indicating no symptoms and 10 indicating severe symptoms.
Subjective burden assessed by visual analogue scale of both tests
assessed by visual analogue scale from 0 to 10, with 0 indicating no symptoms and 10 indicating severe symptoms.
Health care costs of both tests
Frequency of test preference at follow up visit
Full Information
NCT ID
NCT03572166
First Posted
June 4, 2018
Last Updated
July 24, 2023
Sponsor
University Hospital, Basel, Switzerland
Collaborators
University Hospital, Zürich, Wuerzburg University Hospital, Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico, Erasmus Medical Center, Cambridge University Hospitals NHS Foundation Trust, Federal University of Minas Gerais
1. Study Identification
Unique Protocol Identification Number
NCT03572166
Brief Title
Use of Copeptin Measurement After Arginine Infusion for the Differential Diagnosis of Diabetes Insipidus - the CARGOx Study
Acronym
CARGOx
Official Title
Use of Copeptin Measurement After Arginine Infusion for the Differential Diagnosis of Diabetes Insipidus - the CARGOx Study
Study Type
Interventional
2. Study Status
Record Verification Date
July 2023
Overall Recruitment Status
Completed
Study Start Date
September 3, 2018 (Actual)
Primary Completion Date
September 30, 2022 (Actual)
Study Completion Date
December 31, 2022 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
University Hospital, Basel, Switzerland
Collaborators
University Hospital, Zürich, Wuerzburg University Hospital, Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico, Erasmus Medical Center, Cambridge University Hospitals NHS Foundation Trust, Federal University of Minas Gerais
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
The differential diagnosis of central diabetes insipidus (cDI) is difficult and the current test with the highest diagnostic accuracy is copeptin measurement after hypertonic saline infusion (HIS). Although the HIS improved diagnostic accuracy compared to the standard water deprivation test used for decades before, it still comprises great discomfort for patients due to the rise in serum sodium levels above 149mmol/l and requires the presence of medical staff at all times to guarantee safety of the test.
The arginine stimulation test is routinely used to stimulate growth hormone. Own data in 52 patients with polyuria / polydipsia syndrome showed that arginine infusion is a potent stimulator of the neurohypophysis and provides a new diagnostic tool in the differential diagnosis of cDI. Copeptin measurements upon arginine stimulation (CAS) discriminated patients with diabetes insipidus vs. patients with primary polydipsia with a high diagnostic accuracy of 94%.
To validate these results and to compare them against the HIS a large multicenter trial is needed, where the diagnostic accuracy of the CAS is compared to the HIS.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Diabetes Insipidus, Polydipsia, Primary
Keywords
Copeptin
7. Study Design
Primary Purpose
Diagnostic
Study Phase
Not Applicable
Interventional Study Model
Crossover Assignment
Model Description
Observational randomized cross-over diagnostic international multicenter study
Masking
Outcomes Assessor
Allocation
Randomized
Enrollment
177 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Arginine Infusion
Arm Type
Experimental
Arm Description
Arginine Stimulation Test
Arm Title
Hypertonic saline infusion
Arm Type
Active Comparator
Arm Description
Hypertonic Saline Infusion Test
Intervention Type
Diagnostic Test
Intervention Name(s)
Arginine infusion
Intervention Description
Intravenous Infusion of Arginine is given, copeptin measurement will be collected before and 60minutes after start of infusion
Intervention Type
Diagnostic Test
Intervention Name(s)
Hypertonic saline infusion
Intervention Description
Intravenous Infusion of hypertonic Saline is given, copeptin measurement will be collected before and once Plasma sodium rises above 149mmol/l
Primary Outcome Measure Information:
Title
The primary outcome is the overall diagnostic accuracy - defined as the proportion of correct diagnoses - of each diagnostic procedure in differentiating patients with central diabetes insipidus from patients with primary polydipsia.
Description
For Arginine stimulation the copeptin cut-off to differentiate between diabetes insipidus and primary polydipsia will be 3.8 pmol/l after 60 minutes, for hypertonic saline stimulation it will be the copeptin cut-off 4.9 pmol/l taken at the end of the test
Time Frame
2 days
Secondary Outcome Measure Information:
Title
Sensitivity of both diagnostic procedures for each diagnosis (Primary polydipsia, partial and complete central Diabetes insipidus) according to recommended diagnostic test criteria and previously generated cutoff values
Description
Copeptin cut-offs used:
Arginine stimulation:
Copeptin level at 60 minutes < 2.4 pmol/l = complete central diabetes insipidus
Copeptin level at 60 minutes 2.4 - 3.8 pmol/l = partial central diabetes insipidus
Copeptin level at 60 minutes > 3.8 pmol/l = primary polydipsia
Hypertonic saline stimulation:
Copeptin level < 2.7 pmol/l = complete central diabetes insipidus
Copeptin level 2.7 - 4.9 pmol/l = partial central diabetes insipidus
Copeptin level > 4.9 pmol/l = primary polydipsia
Time Frame
2 days (1 day for each test, evaluation diagnostic accuracy at end of trial)
Title
Specificity of both diagnostic procedures for each diagnosis (Primary polydipsia, partial and complete central Diabetes insipidus) according to recommended diagnostic test criteria and previously generated cutoff values
Description
Copeptin cut-offs used:
Arginine stimulation:
Copeptin level at 60 minutes < 2.4 pmol/l = complete central diabetes insipidus
Copeptin level at 60 minutes 2.4 - 3.8 pmol/l = partial central diabetes insipidus
Copeptin level at 60 minutes > 3.8 pmol/l = primary polydipsia
Hypertonic saline stimulation:
Copeptin level < 2.7 pmol/l = complete central diabetes insipidus
Copeptin level 2.7 - 4.9 pmol/l = partial central diabetes insipidus
Copeptin level > 4.9 pmol/l = primary polydipsia
Time Frame
2 days (1 day for each test, evaluation diagnostic accuracy at end of trial)
Title
Positive predictive value of both diagnostic procedures for each diagnosis (Primary polydipsia, partial and complete central Diabetes insipidus) according to recommended diagnostic test criteria and previously generated cutoff values
Description
Copeptin cut-offs used:
Arginine stimulation:
Copeptin level at 60 minutes < 2.4 pmol/l = complete central diabetes insipidus
Copeptin level at 60 minutes 2.4 - 3.8 pmol/l = partial central diabetes insipidus
Copeptin level at 60 minutes > 3.8 pmol/l = primary polydipsia
Hypertonic saline stimulation:
Copeptin level < 2.7 pmol/l = complete central diabetes insipidus
Copeptin level 2.7 - 4.9 pmol/l = partial central diabetes insipidus
Copeptin level > 4.9 pmol/l = primary polydipsia
Time Frame
2 days (1 day for each test, evaluation diagnostic accuracy at end of trial)
Title
Negative predictive value of both diagnostic procedures for each diagnosis (Primary polydipsia, partial and complete central Diabetes insipidus) according to recommended diagnostic test criteria and previously generated cutoff values
Description
Copeptin cut-offs used:
Arginine stimulation:
Copeptin level at 60 minutes < 2.4 pmol/l = complete central diabetes insipidus
Copeptin level at 60 minutes 2.4 - 3.8 pmol/l = partial central diabetes insipidus
Copeptin level at 60 minutes > 3.8 pmol/l = primary polydipsia
Hypertonic saline stimulation:
Copeptin level < 2.7 pmol/l = complete central diabetes insipidus
Copeptin level 2.7 - 4.9 pmol/l = partial central diabetes insipidus
Copeptin level > 4.9 pmol/l = primary polydipsia
Time Frame
2 days (1 day for each test, evaluation diagnostic accuracy at end of trial)
Title
Best fit diagnostic copeptin cut-off values for differentiation between each diagnosis (Primary polydipsia, partial and complete central Diabetes insipidus) upon arginine stimulation and hypertonic saline infusion stimulation
Time Frame
2 days (1 day for each test, evaluation diagnostic accuracy at end of trial)
Title
Accuracy of the copeptin cut-off of 3.7 pmol/l after 60 minutes and 4.1 after 90 minutes for Arginine Stimulation test
Time Frame
2 days (1 day for each test, evaluation diagnostic accuracy at end of trial)
Title
Sensitivity of the copeptin cut-off of 3.7 pmol/l after 60 minutes and 4.1 after 90 minutes for Arginine Stimulation test
Time Frame
2 days (1 day for each test, evaluation diagnostic accuracy at end of trial)
Title
Specificity of the copeptin cut-off of 3.7 pmol/l after 60 minutes and 4.1 after 90 minutes for Arginine Stimulation test
Time Frame
2 days (1 day for each test, evaluation diagnostic accuracy at end of trial)
Title
Accuracy of the copeptin cut-off of 6.5 pmol/l for Hypertonic Saline Infusion test
Time Frame
2 days (1 day for each test, evaluation diagnostic accuracy at end of trial)
Title
Sensitivity of the copeptin cut-off of 6.5 pmol/l for Hypertonic Saline Infusion test
Time Frame
2 days (1 day for each test, evaluation diagnostic accuracy at end of trial)
Title
Specificity of the copeptin cut-off of 6.5 pmol/l for Hypertonic Saline Infusion test
Time Frame
2 days (1 day for each test, evaluation diagnostic accuracy at end of trial)
Title
Frequency and severity of thirst assessed by visual analogue scale during both tests
Description
assessed by visual analogue scale from 0 to 10, with 0 indicating no symptoms and 10 indicating severe symptoms.
Time Frame
2 days (1 for each test)
Title
Frequency and severity of headache assessed by visual analogue scale during both tests
Description
assessed by visual analogue scale from 0 to 10, with 0 indicating no symptoms and 10 indicating severe symptoms.
Time Frame
2 days (1 for each test)
Title
Frequency and severity of nausea assessed by visual analogue scale during both tests
Description
assessed by visual analogue scale from 0 to 10, with 0 indicating no symptoms and 10 indicating severe symptoms.
Time Frame
2 days (1 for each test)
Title
Frequency and severity of vertigo assessed by visual analogue scale during both tests
Description
assessed by visual analogue scale from 0 to 10, with 0 indicating no symptoms and 10 indicating severe symptoms.
Time Frame
2 days (1 for each test)
Title
Frequency and severity of general malaise assessed by visual analogue scale during both tests
Description
assessed by visual analogue scale from 0 to 10, with 0 indicating no symptoms and 10 indicating severe symptoms.
Time Frame
2 days (1 for each test)
Title
Subjective burden assessed by visual analogue scale of both tests
Description
assessed by visual analogue scale from 0 to 10, with 0 indicating no symptoms and 10 indicating severe symptoms.
Time Frame
2 days (1 for each test)
Title
Health care costs of both tests
Time Frame
2 days (1 for each test)
Title
Frequency of test preference at follow up visit
Time Frame
30 days
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
95 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Age ≥ 18 years
Hypotonic polyuria / polydipsia syndrome defined as: polyuria >50ml/kg body weight/24h and polydipsia >3l /24h or known diabetes insipidus under treatment with DDAVP
Urine-Osmolality <800mOsm/L
Exclusion Criteria:
Polyuria / polydipsia secondary to diabetes mellitus, hypercalcemia or hypokalemia
Nephrogenic diabetes insipidus (defined as baseline copeptin level >21.4pmol/L)
Evidence of any acute illness
Epilepsy requiring treatment
Uncontrolled arterial hypertension (blood pressure >160/100mmHg at baseline)
Cardiac failure (NYHA III-IV)
Liver cirrhosis (Child B-C)
Uncorrected adrenal or thyroidal deficiency
Patients refusing or unable to give written informed consent
Pregnancy or breast feeding
End of life care
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Mirjam Christ-Crain, Prof, MD
Organizational Affiliation
University Hospital, Basel, Switzerland
Official's Role
Principal Investigator
Facility Information:
Facility Name
Hospital das clinicas Minas Gerais
City
Belo Horizonte
Country
Brazil
Facility Name
University Hospital Würzburg
City
Würzburg
Country
Germany
Facility Name
Granda Ospedale Maggiore Policlinico Milan
City
Milan
Country
Italy
Facility Name
Erasmus MC
City
Rotterdam
Country
Netherlands
Facility Name
University Hospital Basel, Department of Endocrinology
City
Basel
State/Province
Basel Stadt
ZIP/Postal Code
4031
Country
Switzerland
Facility Name
University Hospital Zurich
City
Zürich
Country
Switzerland
Facility Name
Cambridge University Hospital
City
Cambridge
Country
United Kingdom
12. IPD Sharing Statement
Learn more about this trial
Use of Copeptin Measurement After Arginine Infusion for the Differential Diagnosis of Diabetes Insipidus - the CARGOx Study
We'll reach out to this number within 24 hrs